Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal developmentJCI INSIGHTIF6.12023-11-083OA
Delivering therapeutic lysosomal enzyme to the CNS: A rapid, large-scale in vivo screen identifies optimal characteristics of BBB-crossing TFRC antibodiesMOLECULAR GENETICS AND METABOLISMIF3.52023-02-011PRE
Defining phenotype reversibility in lysosomal disease: Leveraging a COIN model in mucopolysaccharidosis type VI (MPS VI)MOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Liver-specific AAV gene therapy corrects lipid storage in LAL-D model mice but does not prevent lipid accumulation in acquired fatty liver model miceMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
BBB-targeted GAA delivered as gene therapy treats CNS and muscle in Pompe disease model miceMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapiesMOLECULAR THERAPYIF122021-12-0115OAAI
Next-generation antibody-guided enzyme replacement therapy in Pompe disease miceMOLECULAR GENETICS AND METABOLISMIF3.52018-02-014PREAI